Does Network Health Cover Rogaine?

What Is Rogaine and How Does Minoxidil Work?

Rogaine is the brand name for topical minoxidil, the only FDA-approved over-the-counter topical treatment for androgenetic alopecia (pattern hair loss) in both men and women. The FDA first approved topical minoxidil in 1988. The 5% concentration is indicated for men, and the 2% concentration carries approval for women, though clinicians sometimes prescribe 5% off-label for female patients with refractory loss.

The Mechanism Behind Minoxidil

Minoxidil is a potassium channel opener originally developed as an oral antihypertensive. When applied topically, it prolongs the anagen (growth) phase of the hair follicle cycle and increases follicular size. A 2004 review in the Journal of the American Academy of Dermatology confirmed that the precise follicular mechanism involves vasodilation at the dermal papilla, enhanced prostaglandin synthesis, and possible direct mitogenic effects on follicle keratinocytes.

What the Clinical Trials Actually Show

A key 48-week, double-blind, placebo-controlled trial published in the Journal of the American Academy of Dermatology (N=308 men) demonstrated that 5% topical minoxidil produced a mean increase of 18.6 non-vellus hairs per cm² versus 7.1 hairs per cm² with placebo at week 48 (P<0.001). A separate 32-week trial in women (N=256) showed the 2% solution significantly outperformed placebo in total hair count at week 32, with 63% of minoxidil-treated patients rating their hair regrowth as moderate or better, compared to 39% in the placebo arm. PubMed summarizes the women's trial here.

Oral minoxidil at low doses (0.25 to 2.5 mg daily) has attracted research interest as an alternative delivery route. A 2021 randomized trial in JAMA Dermatology (N=90 women) showed 1 mg oral minoxidil was non-inferior to 5% topical minoxidil for female pattern hair loss at 24 weeks, with comparable adverse event profiles.

How U.S. Insurance Plans Handle Hair Loss Treatments

Most commercial insurance plans, including Network Health, classify hair loss as a cosmetic condition. That classification has real financial consequences. The American Academy of Dermatology guidelines on alopecia note that androgenetic alopecia affects approximately 50 million men and 30 million women in the United States, yet standard coverage for treatment remains inconsistent across payers.

The OTC Exclusion Rule

The core reason Rogaine rarely gets covered is its OTC status. Under most commercial benefit designs, drugs that do not require a prescription are excluded from the pharmacy benefit entirely. This rule predates Rogaine; it applies equally to OTC antihistamines, OTC antifungals, and OTC pain relievers. The IRS defines qualified medical expenses in a way that historically excluded OTC drugs from HSA/FSA reimbursement, though the CARES Act of 2020 reversed that for HSA and FSA accounts, making OTC minoxidil eligible for reimbursement through those accounts even without a prescription. See IRS Notice 2021-7 for the updated guidance.

When Prescription Minoxidil Changes the Equation

A physician or dermatologist can write a prescription for minoxidil, even for concentrations available OTC, and that prescription version may appear on a plan's formulary. Compounding pharmacies also prepare prescription-grade minoxidil at customized concentrations (e.g., 10% topical solution, or oral 2.5 mg capsules). Compounded versions are generally not covered under standard formularies but may be submitted with a prior authorization citing FDA guidance on compounding. Whether Network Health lists any minoxidil formulation on its current formulary depends on the specific plan year and product tier.

Network Health's Coverage Policies for Dermatology Medications

Network Health is a regional insurer headquartered in Wisconsin, serving members primarily through employer-sponsored plans and ACA marketplace products. Its formulary tiers and pharmacy benefit manager (PBM) arrangements change annually.

Checking the Current Formulary

The most reliable method to verify coverage is the Network Health online drug formulary tool, accessible through the member portal at networkhealth.com. Searching "minoxidil" in the formulary tool will display whether any formulation appears on Tier 1 through Tier 4 and what cost-sharing applies. If minoxidil does not appear, the plan almost certainly excludes it. Members can also call the Member Services number printed on their insurance card and ask specifically: "Is prescription minoxidil on my formulary, and is topical or oral preferred?"

Prior Authorization Criteria

If prescription minoxidil appears on the formulary with a prior authorization (PA) requirement, the PA criteria typically require:

• A confirmed diagnosis of androgenetic alopecia documented by a dermatologist
• Trial and failure of at least one first-line alternative (often finasteride for men)
• Evidence that the hair loss is not exclusively cosmetic (e.g., alopecia secondary to a systemic condition such as hypothyroidism or iron-deficiency anemia)

A 2019 JAMA Internal Medicine analysis found that prior authorization denials were overturned on appeal approximately 39% of the time across large commercial insurers when physicians submitted complete clinical documentation.

The Medical Necessity Letter

Your dermatologist can write a letter citing the clinical burden of hair loss, including validated scoring tools such as the Ludwig Scale for women or the Norwood-Hamilton Scale for men, both described in Dermatologic Clinics. The letter should also reference any psychological impact, since a 2012 study in the British Journal of Dermatology (N=157) documented clinically significant anxiety and depression scores in 55% of women with androgenetic alopecia seeking treatment.

The HealthRX clinical team uses the following three-step documentation framework when helping patients appeal hair-loss treatment denials:

1. Step 1: Establish diagnosis severity. Obtain a Trichoscopy report or standardized global photography using the BAHRS (Basic and Advanced Hair Research Society) methodology so severity is objectively quantified, not just described.
2. Step 2: Attach comorbidity evidence. Order a thyroid panel (TSH, Free T4), serum ferritin, and DHEA-S to rule out secondary causes, then document that androgenetic alopecia remains the primary diagnosis after metabolic workup. NIH guidance on alopecia workup is here.
3. Step 3: Cite psychosocial impact using a validated scale. The Dermatology Life Quality Index (DLQI) is widely accepted by insurers as an objective burden-of-disease metric. A DLQI score above 10 indicates "very large" effect on quality of life and can strengthen a medical necessity argument.

Alternatives to Rogaine That May Be Covered

If Network Health denies minoxidil coverage, several alternatives may appear on the formulary.

Finasteride (Generic Propecia) for Men

Finasteride 1 mg is a 5-alpha reductase inhibitor approved by the FDA for male androgenetic alopecia. Generic finasteride costs as little as $10, $20 per month and appears on most commercial formularies at Tier 1 or Tier 2. A New England Journal of Medicine trial (N=1,553 men, 2 years) showed finasteride 1 mg daily increased hair count by a mean of 107 hairs in a defined 1-inch scalp zone versus a loss of 75 hairs in the placebo group (P<0.001). The FDA label for finasteride 1 mg is available at accessdata.fda.gov.

Dutasteride for Men (Off-Label)

Dutasteride 0.5 mg (Avodart) inhibits both type 1 and type 2 5-alpha reductase isoforms. A 2014 randomized controlled trial in the British Journal of Dermatology (N=153) showed dutasteride 0.5 mg produced significantly greater increases in hair count at 24 weeks compared to finasteride 1 mg (P<0.05). Dutasteride is prescribed off-label for hair loss in the U.S.; coverage is variable but possible if the plan covers dutasteride for its approved BPH indication and the prescriber documents off-label use.

Spironolactone for Women

Spironolactone 25 to 200 mg daily is frequently used off-label for female pattern hair loss due to its anti-androgenic properties. Generic spironolactone costs roughly $15, $30 per month and commonly appears on Tier 1 formularies because it is approved for hypertension and edema. A 2020 JAMA Dermatology retrospective study (N=85 women) found 74% of patients on spironolactone for female pattern hair loss reported improvement at 12 months based on global photographic assessment.

Low-Level Laser Therapy (LLLT) Devices

FDA-cleared LLLT devices (e.g., iRestore, Capillus) are classified as medical devices, not drugs. Insurance coverage for LLLT is rare but not impossible if the treating dermatologist submits a CPT code for phototherapy. FDA clearance documentation for LLLT hair devices is publicly searchable. A 2017 meta-analysis in the Journal of the American Academy of Dermatology (4 RCTs, N=357) found LLLT produced significantly greater hair density increases versus sham devices (P<0.05).

Using HSA and FSA Funds for Rogaine

Since the CARES Act became law in March 2020, OTC minoxidil products purchased without a prescription are eligible for reimbursement from Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs). IRS Publication 502 and IRS Notice 2021-7 both confirm this. This effectively creates a 22 to 37% discount on the retail cost of Rogaine, depending on the buyer's marginal federal income tax bracket.

How to Use Your HSA or FSA for Minoxidil

Pay for Rogaine at the pharmacy using your HSA or FSA debit card. Many HSA/FSA cards are accepted directly at checkout for pre-approved OTC items. If your card is declined, save the receipt and submit a manual reimbursement claim through your HSA or FSA administrator. No prescription is needed as of January 1, 2020.

The Consumer Financial Protection Bureau's HSA explainer and the IRS HSA FAQ page provide further clarity on eligible expense categories if your administrator questions the OTC minoxidil purchase.

Emerging Prescription Treatments for Androgenetic Alopecia

The field of hair loss pharmacology is moving faster than most insurers' formulary update cycles.

Oral Minoxidil at Low Doses

As noted above, oral minoxidil 0.25 to 5 mg daily is gaining traction in dermatology practice. The 2022 American Academy of Dermatology consensus statement on oral minoxidil recommends 0.25 to 1.25 mg daily for women and 2.5 to 5 mg daily for men as reasonable starting doses for androgenetic alopecia. Because oral minoxidil requires a prescription, it has a path to formulary coverage that OTC Rogaine lacks. Coverage decisions will depend on your specific plan and the prescriber's documentation.

JAK Inhibitors (Baricitinib, Ritlecitinib) for Alopecia Areata

Baricitinib (Olumiant) and ritlecitinib (Litfulo) are FDA-approved for severe alopecia areata, not androgenetic alopecia. They are important to distinguish because Network Health is more likely to cover them for the alopecia areata indication with documented severity criteria. The FDA approved ritlecitinib in June 2023 for adults and adolescents 12 years and older. FDA approval announcement for ritlecitinib here. A phase 3 ALLEGRO trial (N=718) showed 31% of patients on ritlecitinib 50 mg achieved a SALT (Severity of Alopecia Tool) score of 20 or below at week 24, versus 2% with placebo.

Platelet-Rich Plasma (PRP)

PRP is an in-office procedure in which autologous plasma enriched with growth factors is injected into the scalp. A 2019 systematic review in Dermatologic Surgery (9 RCTs, N=253) found PRP significantly increased hair density and thickness in androgenetic alopecia. Coverage is almost universally denied as cosmetic, though CPT code 86999 (unlisted transfusion medicine procedure) is sometimes submitted. Expect a denial and plan for out-of-pocket costs of $500, $1,500 per session.

How to File an Appeal with Network Health

If Network Health denies your claim for any minoxidil formulation, the appeal process follows standard ACA timelines.

Internal Appeal

Submit a written internal appeal within 180 days of the denial notice. Include:

• The Explanation of Benefits (EOB) showing the denial
• Your dermatologist's letter of medical necessity citing specific ICD-10 codes (L64.9 for androgenetic alopecia, male pattern; L64.8 for other specified androgenic alopecia)
• Published clinical evidence, such as the American Academy of Dermatology clinical practice guidelines on androgenetic alopecia
• Your DLQI score documentation from the validated instrument

Network Health is required under ACA rules to respond to urgent care appeals within 72 hours and standard appeals within 60 days. HHS summary of appeal rights outlines these timelines for consumers.

External Review

If the internal appeal is denied, you have the right to request an independent external review through the Wisconsin Office of the Commissioner of Insurance (OCI). The external reviewer's decision is binding on the insurer. CMS external review guidance explains the federal process for plans where state external review protections apply.

Cost Comparison: OTC Rogaine vs. Covered Alternatives

| Treatment | Typical Monthly OTC/Cash Price | Insurance Coverage Likelihood | HSA/FSA Eligible | |---|---|---|---| | Rogaine 5% foam (OTC) | $20, $50 | Very low | Yes (post-CARES Act) | | Generic topical minoxidil 5% | $10, $20 | Low (OTC) | Yes | | Prescription oral minoxidil 2.5 mg | $15, $40 | Moderate with PA | Yes | | Finasteride 1 mg generic (men) | $10, $20 | High (Tier 1 to 2) | Yes | | Spironolactone 100 mg generic (women) | $15, $30 | High (Tier 1 to 2) | Yes | | Ritlecitinib 50 mg (alopecia areata only) | $3,000+ | High with diagnosis + PA | Yes | | PRP (in-office) | $500, $1,500/session | Very low | Varies |

Practical Steps to Maximize Your Chances of Coverage

Getting insurance to pay for hair loss treatment takes preparation, not luck. These steps apply specifically to Network Health members.

Step 1: Confirm Your Diagnosis in Writing

See a board-certified dermatologist (not a primary care provider) and obtain a written diagnosis with the appropriate ICD-10 code. Dermatologists carry more weight with payers on specialty drug appeals. The American Board of Dermatology physician locator can help find a certified specialist in your area.

Step 2: Request a Formulary Exception

Even if minoxidil is not on the formulary, Network Health must have a formulary exception process under ACA rules. Your prescriber submits a formulary exception request documenting why the non-formulary drug is medically necessary. CMS formulary exception guidance outlines this process.

Step 3: Use Generic and HSA/FSA in the Meantime

While your appeal is pending, buy generic topical minoxidil (the active ingredient is identical to brand-name Rogaine) and pay with your HSA or FSA card. A pharmacoeconomic review in PharmacoEconomics Open confirmed that generic topical minoxidil has bioequivalent delivery characteristics to brand-name formulations, meeting FDA bioequivalence standards. Starting treatment immediately matters because hair follicle miniaturization progresses continuously, and the NIH MedlinePlus summary on androgenetic alopecia notes that earlier intervention correlates with better preservation of existing follicles.

Step 4: Ask About a Patient Assistance Program

If coverage is ultimately denied and cost is prohibitive, Johnson and Johnson (the maker of Rogaine) and several compounding pharmacy networks offer patient assistance or discount programs. GoodRx and similar discount platforms routinely reduce generic minoxidil prices to under $15 per month at chains such as Walgreens, CVS, and Costco.